Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer

NCT04142554 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Funding withdrawn from funding source.

Conditions

Breast Cancer
Breast Neoplasms
Triple Negative Breast Cancer
HER2-positive Breast Cancer

Interventions

DRUG: Parsaclisib

Sponsor

UNC Lineberger Comprehensive Cancer Center

Collaborators

[object Object]